Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Children's Oncology Group National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00003096 |
RATIONALE: Analyzing the number and structure of genes found in a child's cancer cells may help doctors improve methods of diagnosing and treating children with brain tumors.
PURPOSE: This clinical trial is studying the number and structure of genes in cancer cells of children with brain tumors.
Condition | Intervention |
---|---|
Brain and Central Nervous System Tumors |
Procedure: DNA ploidy analysis Procedure: comparative genomic hybridization Procedure: cytogenetic analysis Procedure: fluorescence in situ hybridization |
Study Type: | Observational |
Official Title: | Molecular Biology of Pediatric Brain Tumors |
Study Start Date: | December 1997 |
OBJECTIVES:
OUTLINE: DNA ploidy analysis will be performed to determine the overall level of aneuploidy. The results are compared to the comparative genomic hybridization (CGH) analysis, which is used to demonstrate tumor-specific losses or gains, including amplification, of specific chromosomal regions. Tumors are also screened for specific abnormalities by fluorescent in situ hybridization (FISH), which detects chromosomal rearrangements, including balanced translocations, deletions, amplifications, etc. PCR-based microsatellite polymorphism analysis may also be performed.
Primitive neuroectodermal tumors (PNETs) are screened by FISH with a distal 17p13.3 cosmid and a 17q25 cosmid to identify tumors with a 17p deletion. Atypical teratoid/rhabdoid tumors and PNETs without a 17p deletion are screened by FISH with a series of cosmids from 22q11.2. PNETs are also screened by interphase FISH with cosmids from chromosome 6 to identify tumors with deletions.
Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
PROJECTED ACCRUAL: This study will accrue 360 specimens.
Ages Eligible for Study: | up to 20 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy
Radiotherapy
Surgery
Study Chair: | Jaclyn A. Biegel, PhD | Children's Hospital of Philadelphia |
Study ID Numbers: | CDR0000065814, COG-B971, CCG-B971 |
Study First Received: | November 1, 1999 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00003096 |
Health Authority: | United States: Federal Government |
untreated childhood supratentorial primitive neuroectodermal tumor untreated childhood medulloblastoma |
Neuroectodermal Tumors Brain Neoplasms Neuroectodermal Tumors, Primitive Medulloblastoma Neuroepithelioma |
Central Nervous System Diseases Central Nervous System Neoplasms Brain Diseases Nervous System Neoplasms |
Neoplasms Neoplasms by Site Nervous System Diseases |